Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics of MK-8527 With Rifampin in Latent Tuberculosis Infection
NCT07600775Phase 1Not yet recruiting
- Sponsor
- Merck & Co.
- Start
- Sep 2026
- Primary completion
- Jan 2027
- Modality
- Small Molecules
01
Overview
Phase 1, open-label, single-arm trial of mk-8527 in human immunodeficiency virus infection (HIV), sponsored by Merck & Co. Primary endpoint: Area Under the Concentration-Time Curve From Time Zero to Infinity up to 2 weeks. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
mk-8527
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT07600775.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07600775.